CCM
RVPHW

Context Capital Management’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

Context Capital Management’s Portfolio RVPHW Stock Details RVPHW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,300
Closed -$18K – 528
2021
Q1 		$18K Hold
39,300
– – ﹤0.01% 449
2020
Q4 		$27K Buy
+39,300
New +$21.6K ﹤0.01% 256

Other funds holding RVPHW

BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Context Capital Management's RVPHW Position: Q2 2021 in Review

Context Capital Management sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q2 2021, closing a stake of 39,300 shares — an estimated $18K sold.

Context Capital Management first reported a position in RVPHW in Q4 2020 and held it in 2 quarters. The position peaked at $27K in Q4 2020. 10 funds tracked by Wall St. Rank hold RVPHW as of Q2 2021.

  • Context Capital Management reported no remaining Reviva Pharmaceuticals Warrants position as of Q2 2021 after selling out during the quarter.
  • Context Capital Management sold 39,300 Reviva Pharmaceuticals Warrants shares in Q2 2021, an estimated $18K.
  • Context Capital Management first reported a position in Reviva Pharmaceuticals Warrants in Q4 2020 and held it in 2 quarters.
  • Context Capital Management's Reviva Pharmaceuticals Warrants position peaked at $27K in Q4 2020.
  • 10 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q2 2021.

Based on Context Capital Management's 13F filing for Q2 2021, filed 17 Aug 2021.